Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41

Benzinga · 2d ago
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $40 to $41.